MedTrace Logo

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis

NCT06260878 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 505

Last updated 2026-04-29

No results posted yet for this study

Summary

This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.

Conditions

  • Post-ERCP Acute Pancreatitis

Interventions

OTHER

Intravenous Ringer's lactate

Intravenous Ringer's lactate

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-22
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06260878 on ClinicalTrials.gov